Rex Bionics PLC Result of AGM (3795X)
August 28 2015 - 2:02AM
UK Regulatory
TIDMRXB
RNS Number : 3795X
Rex Bionics PLC
28 August 2015
Rex Bionics Plc
("Rex Bionics" or the "Company")
Results of Annual General Meeting
28 August 2015: Rex Bionics Plc (AIM: RXB), the pioneer of the
REX Robot technology that enhances the mobility of wheel-chair
users and enables robot assisted physiotherapy exercise, today
announces that at its Annual General Meeting held on 27(th) August
2015 at the offices of Simmons & Simmons, CityPoint, 1
Ropemaker St, London EC2Y 9HT, all resolutions proposed were duly
passed as follows:
1. To receive the Report of the Directors and Financial
Statements for the period ending 31 March 2015 together with the
report from the auditors.
2. To approve the Remuneration Report of the Board as set out in the Financial Statements.
3. To reappoint Messrs Grant Thornton, Chartered Accountants and
Statutory Auditors, as auditors of the Company and authorize the
Directors to fix their remuneration.
4. To reappoint as a Director Bill Hunter who retires in
accordance with Article 35.2 and offers himself for
reappointment.
5. To re-elect as a Director Peter Worrall who retires in
accordance with Article 35.2 and offers himself for
re-election.
6. That the Board is generally and unconditionally authorized in
accordance with Section 551 of the Companies Act 2006 as amended
(the "Act") such authority to replace all existing authorities
granted to the Board pursuant to section 551 of the Act to allot
relevant securities (within the meaning of section 551 of the Act)
provided that this power is limited to a maximum aggregate amount
of GBP593,700, such authority to expire on the conclusion of the
Company's annual general meeting to be held in 2016, save that the
Company may prior to such expiry make an offer or agreement which
would or might require relevant securities to be allotted or
granted after the expiry of such period and the Board may allot
relevant securities in pursuance of any such offer or agreement as
if the authority had not expired.
7. Special Resolution: That the Board be and is generally
empowered in accordance with section 570 of the Act to allot
securities (as defined in section 560(1) of the Act) for cash,
pursuant to the authority conferred on it by Resolution 6, as if
section 561 (1) of the Act did not apply to any such allotment,
such authority to replace all existing authorities up to an
aggregate nominal amount of GBP178,300 and shall expire on the
conclusion of the annual general meeting to be held in 2016, save
that the Company may prior to such expiry make an offer or
agreement which would or might require equity securities to be
allotted after expiry of the said period and the Board may allot
equity securities in pursuance of such an offer or agreement as if
the power had not expired.
For further information please contact:
Rex Bionics Plc
Crispin Simon, Chief Executive Officer
+44 (0) 781 086 6386
Peter Worrall, Chief Financial Officer
+44 (0)1428 645416
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior/Giles Balleny
+44 (0) 20 7710 7600
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Lindsey
Neville
rexbionics@consilium-comms.com
+44 (0) 203 709 5700
About Rex Bionics Plc
Rex Bionics (AIM: RXB) is the AIM-listed pioneer of the REX
Robot that enhances the mobility of wheelchair users. Founded in
Auckland, New Zealand by two robotics engineers with first-hand
experience of wheelchair users and their needs, Rex Bionics is
working with physiotherapists to develop the practice of
Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts
patients from a sitting position into a robot-supported standing
position, allowing them to take part in a set of supported walking
and stretching exercises, designed by specialist
physiotherapists.
Wheelchair users are at risk of developing numerous medical
complications from extended periods of sitting. By enabling them to
spend more time standing, walking and exercising, REX may offer
significant health benefits, including improved sleep,
cardiovascular performance, maintenance of joint range, and a
reduction in common abdominal problems and prescription drug use. A
programme of clinical trials is now under way to evaluate these
potential benefits.
REX is used by people with complete spinal cord injury, as well
as people who have suffered a stroke or other traumatic brain
injury; and people with multiple sclerosis and muscular dystrophy.
REX P, for use in the home, enables users to walk and stand with
their hands free - providing more work and recreation options.
Rex Bionics has been listed on AIM since April 2014. REX is not
approved for At-Home use in the United States of America.
For more information please visit, www.rexbionics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGPGUCURUPAPGM
(END) Dow Jones Newswires
August 28, 2015 02:02 ET (06:02 GMT)
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Sep 2023 to Sep 2024